Awarded FIRST PLACE

Concenter BioPgharma' Type 2 Diabetes Drug - "Zygosid-50" has been awarded FIRST PLACE.


Prof. Mottie Chevion, CSO, received the award from Zachary Bloomgarden, MD.

At the 17th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC), December 7th, 2019 in Los Angeles. Prof. Mottie Chevion, CSO, received the award from Zachary Bloomgarden, MD.


It is a great honor to receive this recognition for our achievements from the global leading researchers, physicians-clinicians and other healthcare professionals in the field!


The Congress is the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance, linking basic research to clinical practice in pursuit of the theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.


LINKS TO Congress Website






Recent Posts

See All

ANNUAL BIOTECH IN EUROPE FORUM 2019

Come see us and hear our presentation at the 19TH ANNUAL BIOTECH IN EUROPE FORUM FOR GLOBAL PARTNERING & INVESTMENT (25TH-26TH SEPTEMBER 201

Hi, thanks for stopping by!

Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications. 

 

Our PLATFORM is the result of extensive investigation of animal models of human diseases.

Let the news
come to you.

  • LinkedIn
  • Facebook
  • Twitter

CONTACT US

Thank you for your interest in Concenter BioPharma.

To contact us please reach us via: